{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:52:58Z","timestamp":1783655578695,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd014941","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000}}],"reference-count":35,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014941.pub2","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T11:57:50Z","timestamp":1722513470000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cenobamate add-on therapy for drug-resistant focal epilepsy"],"prefix":"10.1002","volume":"2024","author":[{"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[{"name":"Innovation, Research and Teaching Service (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical Private University (PMU); Bolzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lattanzi","sequence":"additional","affiliation":[{"name":"Neurological Clinic; Marche Polytechnic University; Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"issue":"22","key":"10.1002\/14651858.CD014941.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD014941.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD014941.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ane.13659","article-title":"Onset of efficacy and adverse events during cenobamate titration period","volume":"146","author":"Steinhoff","year":"2022","journal-title":"Acta Neurologica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD014941.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/cts.13167","article-title":"Pharmacokinetics and safety of cenobamate, a novel antiseizure medication, in healthy Japanese, and an ethnic comparison with healthy non-Japanese","volume":"15","author":"Yang","year":"2022","journal-title":"Clinical and Translational Science"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0005|cit5","unstructured":"A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of cenobamate adjunctive therapy in subjects with primary generalized tonic-clonic seizures www.clinicaltrialsregister.eu\/ctr-search\/search?query=2018-001337-41"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0006|cit6","unstructured":"Clinical study to evaluate the efficacy and safety of cenobamate in subjects with partial onset seizures rctportal.niph.go.jp\/en\/detail?trial_id=jRCT2031200405"},{"issue":"3","key":"10.1002\/14651858.CD014941.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1060028020941113","article-title":"Cenobamate: a new adjunctive agent for drug-resistant focal onset epilepsy","volume":"55","author":"Buckley","year":"2021","journal-title":"Annals of Pharmacotherapy"},{"issue":"7","key":"10.1002\/14651858.CD014941.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1528-1167.2011.03047.x","article-title":"Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis","volume":"52","author":"Costa","year":"2011","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD014941.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1358\/dot.2020.56.4.3127030","article-title":"Cenobamate for the treatment of focal epilepsy","volume":"56","author":"Dhir","year":"2020","journal-title":"Drugs of Today (Barcelona)"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0010|cit10","unstructured":"European Medicines Agency Ontozry cenobamate www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ontozry"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0011|cit11","unstructured":"European Medicines Agency Glossary of regulatory terms www.ema.europa.eu\/en\/about-us\/glossaries\/glossary-regulatory-terms"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0012|cit12","unstructured":"FDA approves new treatment for adults with partial-onset seizures www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-adults-partial-onset-seizures"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0013|cit13","unstructured":"Cenobamate full prescribing information www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212839s000lbl.pdf"},{"issue":"3","key":"10.1002\/14651858.CD014941.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD014941.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","article-title":"Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)","volume":"46","author":"Fisher","year":"2005","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD014941.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41582-019-0309-7","article-title":"Cenobamate for focal seizures - a game changer?","volume":"16","author":"French","year":"2020","journal-title":"Nature Reviews Neurology"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0018|cit18","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0019|cit19","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0020|cit20","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"5","key":"10.1002\/14651858.CD014941.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/epi.13723","article-title":"The impact of seizures on epilepsy outcomes: a national, community-based survey","volume":"58","author":"Josephson","year":"2017","journal-title":"Epilepsia"},{"issue":"10","key":"10.1002\/14651858.CD014941.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMra1004418","article-title":"Drug-resistant epilepsy","volume":"365","author":"Kwan","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD014941.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","article-title":"Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis","volume":"34","author":"Lattanzi","year":"2020","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1002\/14651858.CD014941.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","article-title":"Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis","volume":"82","author":"Lattanzi","year":"2022","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","article-title":"The consequences of refractory epilepsy and its treatment","volume":"37","author":"Laxer","year":"2014","journal-title":"Epilepsy & Behavior"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0026|cit26","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"108429","DOI":"10.1016\/j.yebeh.2021.108429.","article-title":"Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures","volume":"126","author":"Privitera","year":"2022","journal-title":"Epilepsy & Behavior"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0028|cit28","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"6","key":"10.1002\/14651858.CD014941.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","article-title":"Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug Interactions and tolerability","volume":"35","author":"Roberti","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0031|cit31","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD014941.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"117957352110702","DOI":"10.1177\/11795735211070209","article-title":"Cenobamate for treatment-resistant focal seizures: current evidence and place in therapy","volume":"14","author":"Singh","year":"2022","journal-title":"Journal of Central Nervous System Disease"},{"issue":"2","key":"10.1002\/14651858.CD014941.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1535759720903032","article-title":"Remarkably high efficacy of cenobamate in adults with focal-onset seizures: a double-blind, randomized, placebo-controlled trial","volume":"20","author":"Vossler","year":"2020","journal-title":"Epilepsy Currents"},{"issue":"1","key":"10.1002\/14651858.CD014941.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/ane.13422","article-title":"Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: a meta-analysis","volume":"144","author":"Zhang","year":"2021","journal-title":"Acta Neurologica Scandinavica"},{"issue":"12","key":"10.1002\/14651858.CD014941.pub2-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014941","article-title":"Cenobamate add-on therapy for drug-resistant focal epilepsy","author":"Brigo","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T10:46:50Z","timestamp":1743763610000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014941.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Z_INACTIVE_Epilepsy Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014941.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}